| Identification | Back Directory | [Name]
FMOC-L-HYP(BOM)-OH | [CAS]
187223-15-0 | [Synonyms]
Fmoc-Hyp(Bcc)-OH
Fmoc-Hyp(Bom)-OH
FMOC-L-HYP(BOM)-OH
(9H-Fluoren-9-yl)MethOxy]Carbonyl Hyp(Bom)-OH
(4R)-1-Fmoc-4-[[[(2-Boc-amino-ethyl)amino]carbonyl]oxy]-L-proline
N-alpha-(9-fluorenylmethyloxycarbonyl)-L-Hyp(Boc-aminoethylcarbamoyl)
N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-O-(TERT-BUTYLOXYCARBONYLAMINOETHYLCARBAMOYL)-TRANS-L-HYDROXYPROLINE
(2S,4R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(((2-((tert-butoxycarbonyl)amino)ethyl)carbamoyl)oxy)pyrrolidine-2-carboxylic acid
(2S,4R)-4-{[(2-{[(tert-butoxy)carbonyl]amino}ethyl)carbamoyl]oxy}-1-{[(9H-fluoren-9-yl)methoxy]carbonyl}pyrrolidine-2-carboxylic acid
(2S,4R)-4-[[[[2-[[(1,1-Dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-1,2-pyrrolidinedicarboxylic acid 1-(9H-fluoren-9-ylmethyl) ester
1,2-Pyrrolidinedicarboxylic acid, 4-[[[[2-[[(1,1-diMethylethoxy)carbonyl]aMino]ethyl]aMino]carbonyl]oxy]-, 1-(9H-fluoren-9-ylMethyl) ester, (2S,4R)- | [EINECS(EC#)]
630-406-9 | [Molecular Formula]
C28H33N3O8 | [MDL Number]
MFCD07366898 | [MOL File]
187223-15-0.mol | [Molecular Weight]
539.58 |
| Chemical Properties | Back Directory | [Boiling point ]
749.0±60.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [form ]
Solid | [pka]
3.55±0.40(Predicted) | [color ]
White to pink |
| Hazard Information | Back Directory | [Uses]
Fmoc-Hyp(Bom)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Hyp(Bom)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs< | [Synthesis]
Step III: Preparation of Fmoc-(2S,4R)-(4-O-CO-NH-CH2-CH2-NH-Boc)-Pro-OH. the methyl ester obtained in step II was converted to free acid by hydrolysis reaction. This is done by adding 1N sodium hydroxide solution to a mixed solvent of 1,4-dioxane and water for the reaction. This step produced a mixture of H-(2S,4R)-(4-O-CO-NH-CH2-CH2-NH-Boc)-Pro-OH with the target product Fmoc-(2S,4R)-(4-O-CO-NH-CH2-CH2-NH-Boc)-Pro-OH. The reaction yield was 55%. | [IC 50]
Cleavable Linker | [References]
[1] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. DOI:10.1038/nrd.2016.268
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
|
|